Want to see KYTX full AI Analyst Report?
KYTX Stock Chart & Stats
$9.93
-$0.14(-3.63%)
At close: 4:00 PM EST
$9.93
-$0.14(-3.63%)
Day’s Range― - ―
52-Week Range$2.80 - $13.67
Previous CloseN/A
Volume87.17K
Average Volume (3M)1.21M
Market Cap
$452.92M
Enterprise Value$353.65M
Total Cash (Recent Filing)$236.45M
Total Debt (Recent Filing)$33.76M
Price to Earnings (P/E)―
Beta1.84
Next Earnings
Aug 18, 2026EPS Estimate
-0.68Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.28
Shares Outstanding60,795,210
10 Day Avg. Volume1,349,118
30 Day Avg. Volume1,208,063
Financial Highlights & Ratios
PEG Ratio-0.28
Price to Book (P/B)1.79
Price to Sales (P/S)0.00
P/FCF Ratio-2.71
Enterprise Value/Market Cap0.78
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-408.37
Enterprise Value/Ebitda-2.30
Forecast
1Y Price Target
$30.00Price Target Upside202.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-2.87
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Data & Regulatory MomentumRobust Phase 2/registrational results showing rapid, durable clinical benefit and discontinuation of chronic immunotherapies materially strengthen Kyverna's pathway to first approval in stiff person syndrome. Durable efficacy and tolerability improve regulatory and commercial probability over the next 2–6 months.
Low Leverage / Solid Equity BaseVery low leverage and a meaningful equity cushion give Kyverna near-term financial flexibility uncommon for clinical-stage biotechs. This reduces refinancing pressure and supports continued trial execution and milestone delivery across the next several quarters.
Commercial Leadership HireBringing a veteran CCO with proven neurology and rare-disease launch experience signals durable organizational readiness to commercialize miv-cel if approved. This builds lasting commercial capabilities, pricing, and launch planning that matter through regulatory to market transition.
Bears Say
High Cash BurnSustained, large negative operating and free cash flow means Kyverna will likely require additional financing within the 2–6 month window to fund operations and potential commercial build. Persistent burn elevates dilution and execution risk if capital markets or milestones slow.
No Revenue BaseAbsent product revenues, Kyverna depends entirely on external funding and milestone-linked receipts to support growth. This structural lack of operating cash inflow reduces resilience to trial delays and complicates meeting future revenue-based covenants or commercial scale-up requirements.
Tighter Financing Terms & CovenantsRestructured loan terms that link future tranches to revenue and milestones create conditional access to capital and introduce revenue covenants beginning as early as mid-2027. This narrows strategic flexibility and increases execution pressure to hit near-term clinical and commercial targets.
Kyverna Therapeutics, Inc. News
KYTX FAQ
What was Kyverna Therapeutics, Inc.’s price range in the past 12 months?
Kyverna Therapeutics, Inc. lowest stock price was $2.80 and its highest was $13.67 in the past 12 months.
What is Kyverna Therapeutics, Inc.’s market cap?
Kyverna Therapeutics, Inc.’s market cap is $452.92M.
When is Kyverna Therapeutics, Inc.’s upcoming earnings report date?
Kyverna Therapeutics, Inc.’s upcoming earnings report date is Aug 18, 2026 which is in 28 days.
How were Kyverna Therapeutics, Inc.’s earnings last quarter?
Kyverna Therapeutics, Inc. released its earnings results on May 12, 2026. The company reported -$0.66 earnings per share for the quarter, beating the consensus estimate of -$0.752 by $0.092.
Is Kyverna Therapeutics, Inc. overvalued?
According to Wall Street analysts Kyverna Therapeutics, Inc.’s price is currently Undervalued.
Does Kyverna Therapeutics, Inc. pay dividends?
Kyverna Therapeutics, Inc. does not currently pay dividends.
What is Kyverna Therapeutics, Inc.’s EPS estimate?
Kyverna Therapeutics, Inc.’s EPS estimate is -0.68.
How many shares outstanding does Kyverna Therapeutics, Inc. have?
Kyverna Therapeutics, Inc. has 60,795,210 shares outstanding.
What happened to Kyverna Therapeutics, Inc.’s price movement after its last earnings report?
Kyverna Therapeutics, Inc. reported an EPS of -$0.66 in its last earnings report, beating expectations of -$0.752. Following the earnings report the stock price went up 5.376%.
Which hedge fund is a major shareholder of Kyverna Therapeutics, Inc.?
Currently, no hedge funds are holding shares in KYTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kyverna Therapeutics, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$30.00 (202.11% Upside)
$30.00 (202.11% Upside)
Blogger Sentiment
Bullish
KYTX Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 2.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 3.0%
Last 30 Days ▼ 3.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
85.64%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-1.39%
Trailing 12-Months
Company Description
Kyverna Therapeutics, Inc.
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
KYTX Stock 12 Month Forecast
Average Price Target
$30.00
▲(202.11% Upside)
Technical Analysis
Codexis
―
Heron Therapeutics
―
Silence Therapeutics
―
Atea Pharmaceuticals
―
Entrada Therapeutics Inc
―
Ownership Overview
23.23% Insiders
5.87% Mutual Funds
0.30% Other Institutional Investors
62.32% Public Companies and
Individual Investors